Artelo Biosciences' ART27.13 reduces chemotherapy-induced neuropathic pain in preclinical study
ARTL•Repeated doses of ART27.13 reduced touch and heat sensitivity in male and female animals with paclitaxel-induced peripheral neuropathy; the ongoing Phase 2 CAReS trial includes pain endpoints.
1. Preclinical findings
Artelo Biosciences will present nonclinical findings on ART27.13 at the IASP 2026 World Congress on Pain in Bangkok. Repeated dosing reduced touch and heat sensitivity in male and female animals with paclitaxel-induced peripheral neuropathy.
2. Phase 2 trial
The ongoing Phase 2 CAReS trial includes pain endpoints to assess whether these effects translate to cancer patients. ART27.13 is a once-daily oral treatment under development for cancer-related appetite and weight loss.
